关键词: 肝癌, 靶向治疗, 免疫治疗, 临床研究

Abstract: Inventory of key research on hepatocellular carcinoma in 2022        OUYANG Li-ying*, XU Li.  *Department of Critical Care，Sun Yat-sen University Cancer Center，Guangzhou510060，China
Corresponding author：XU Li，E-mail:xuli@sysucc.org.cn
Abstract    Hepatocellular carcinoma（HCC）is one of the most common digestive malignant tumors in China，and most patients are in the progressive or advanced stage when they are diagnosed，with poor prognosis.In 2022，the results of several large-scale prospective clinical studies on the advanced hepatocellular carcinoma were published，many of which are of epoch-making significance.The LAUNCH study demonstrated for the first time that systemic drug therapy combined with regional therapy could improve the overall survival of patients with advanced HCC，while the study from the Sun Yat-sen University Cancer Center suggested that FOLFOX-HAIC as postoperative adjuvant therapy could improve the prognosis of HCC patients with microvascular invasion.In addition，several studies of immune checkpoint inhibitors，whether used as single agent in second line or in combination as the first-line therapy，have made breakthroughs.The clinical studies provide powerful guide for adjusting treatment strategies and drug selection in HCC.However，there are still many clinical treatment issues for HCC，such as drug selection for HCC patients with hepatic insufficiency，that need to be explored in further studies.

Key words: hepatocellular carcinoma, targeted therapy, immuno-therapy, clinical trial